There's been something of a game of musical chairs in the executive ranks of Editas Medicine (NASDAQ: EDIT) over the past couple of years. In this Motley Fool Live video, recorded on Feb. 10, Motley Fool contributors Keith Speights and Brian Orelli discuss what impact Editas' latest CEO change might have on the company. A biotech that you and I have both followed some of the years, Editas Medicine, just announced a change at the top on Monday of this week.
J.P. Morgan’s Cory Kasimov moved bluebird bio to Neutral from Overweight in response to news it is suspending trials of a treatment for sickle cell disease.
Futures fell as SolarEdge led key earnings late. Earlier, JPMorgan and Caterpillar broke out while Apple and Tesla test support.